Birthday Gatherings Increase COVID-19 Risk

Save

How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population. 

Knee Replacement in Obese OA is Cost Effective

Save

Debates over ideal candidates for total knee replacement (TKR) in osteoarthritis patients often excludes those who are obese, but a recent article in the Annals of Internal Medicine suggests that TKR is both effective and cost-effective in obese patients (BMI >40 kg/m²) with

Better Outcomes with Modern T2T in Pregnancy

Save

With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.

Progression from Psoriasis to Psoriatic Arthritis

Save

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).

FINCH 1 Trial Filgotinib in Rheumatoid Arthritis

Save

The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).

Treatment of MIS-C COVID in Kids

Save

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular co

Which patients with psoriasis are at risk to develop PsA?

Save

The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.

EULAR 2021 – Day 4 Report

Save

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

RheumNow Podcast - Best of EULAR 2021

Save

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

How Do You Measure Success When It Comes to SLE?

Save

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Save

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

EULAR 2021 - Day 2 Podcasts

Save

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.

You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com

Listen by Clicking below:

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Save

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.

EULAR 2021 – Day 2 Report

Save

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

EULAR 2021 – Day 1 Report

Save

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Foot Pain Commonly Overlooked in RA

Save

Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.

Best Interventions for Gout Flares

Save

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].